1. Home
  2. MCBS vs VTYX Comparison

MCBS vs VTYX Comparison

Compare MCBS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Inc.

N/A

Current Price

$28.58

Market Cap

816.1M

Sector

Finance

ML Signal

N/A

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

N/A

Current Price

$13.99

Market Cap

990.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MCBS
VTYX
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
816.1M
990.9M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MCBS
VTYX
Price
$28.58
$13.99
Analyst Decision
Hold
Hold
Analyst Count
1
7
Target Price
$31.00
$13.50
AVG Volume (30 Days)
60.2K
3.1M
Earning Date
05-01-2026
01-01-0001
Dividend Yield
3.51%
N/A
EPS Growth
24.75
40.30
EPS
1.96
N/A
Revenue
N/A
N/A
Revenue This Year
$36.76
N/A
Revenue Next Year
$4.83
N/A
P/E Ratio
$14.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.24
$0.90
52 Week High
$31.00
$15.34

Technical Indicators

Market Signals
Indicator
MCBS
VTYX
Relative Strength Index (RSI) 44.28 72.58
Support Level $26.90 $13.89
Resistance Level $29.00 $14.07
Average True Range (ATR) 0.68 0.03
MACD -0.17 -0.11
Stochastic Oscillator 17.29 88.89

Price Performance

Historical Comparison
MCBS
VTYX

About MCBS MetroCity Bankshares Inc.

MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: